Blueprint Medicines Corp Alpha and Beta Analysis
| BPMCDelisted Stock | USD 129.46 0.11 0.09% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Blueprint Medicines Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Blueprint Medicines over a specified time horizon. Remember, high Blueprint Medicines' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Blueprint Medicines' market risk premium analysis include:
Beta 0.0 | Alpha 0.0 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Blueprint |
Blueprint Medicines Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Blueprint Medicines market risk premium is the additional return an investor will receive from holding Blueprint Medicines long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Blueprint Medicines. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Blueprint Medicines' performance over market.| α | 0.00 | β | 0.00 |
Blueprint Medicines Fundamentals Vs Peers
Comparing Blueprint Medicines' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Blueprint Medicines' direct or indirect competition across all of the common fundamentals between Blueprint Medicines and the related equities. This way, we can detect undervalued stocks with similar characteristics as Blueprint Medicines or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Blueprint Medicines' fundamental indicators could also be used in its relative valuation, which is a method of valuing Blueprint Medicines by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Blueprint Medicines to competition |
| Fundamentals | Blueprint Medicines | Peer Average |
| Return On Equity | -0.48 | -0.31 |
| Return On Asset | -0.0975 | -0.14 |
| Profit Margin | (0.28) % | (1.27) % |
| Operating Margin | (0.28) % | (5.51) % |
| Current Valuation | 8.25 B | 16.62 B |
| Shares Outstanding | 64.58 M | 571.82 M |
| Shares Owned By Insiders | 0.80 % | 10.09 % |
Blueprint Medicines Opportunities
Blueprint Medicines Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Blueprint Medicines Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Blueprint or other delisted stocks. Alpha measures the amount that position in Blueprint Medicines Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Blueprint Medicines Upcoming Company Events
As portrayed in its financial statements, the presentation of Blueprint Medicines' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Blueprint Medicines' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Blueprint Medicines' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Blueprint Medicines. Please utilize our Beneish M Score to check the likelihood of Blueprint Medicines' management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Blueprint Medicines
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Blueprint Stock
If you are still planning to invest in Blueprint Medicines Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Blueprint Medicines' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |